IBRX · XBRL financial data

ImmunityBio financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (IBRX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	0	1	0	1	15	113
Revenue from contracts with customers	—	—	0	1	15	113
Cost of goods and services sold	—	—	0	0	0	1
Research and development	64	196	248	232	190	—
Selling, general and administrative	27	135	103	130	169	—
Total operating expenses	92	331	352	363	359	—
Operating income (loss)	(92)	(330)	(351)	(362)	(344)	(256)
Interest income	1	—	—	—	—	—
Interest expense	9	15	64	129	115	61
Other income (expense)	(1)	0	(1)	(2)	(0)	(2)
Income tax expense (benefit)	0	0	0	(0)	0	(0)
Net income (loss)	(92)	(347)	(417)	(583)	(414)	(351)
Earnings per share, basic USD per share	(0.59)	(0.89)	(1.04)	(1.15)	(0.59)	(0.38)
Earnings per share, diluted USD per share	(0.59)	(0.89)	(1.04)	(1.15)	(0.62)	(0.38)
Weighted average shares, basic millions of shares	377	389	400	509	697	920
Weighted average shares, diluted millions of shares	377	389	400	509	700	920

Fiscal years (IBRX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	11	181	105	265	143	88
Marketable securities	61	136	3	1	6	154
Marketable securities, non-current	1	1	1	1	0	—
Accounts receivable	—	—	—	0	2	43
Inventory	—	—	—	0	8	1
Prepaid and other current assets	9	16	32	26	24	29
Total current assets	75	334	141	294	185	315
Property and equipment, net	54	83	144	146	137	114
Right-of-use asset	13	36	46	37	33	33
Goodwill	—	—	—	—	1	1
Total assets	152	469	362	504	383	502
Accounts payable	4	11	21	—	—	—
Accrued liabilities	8	51	42	43	41	47
Total current liabilities	25	369	501	58	55	62
Lease liability, non-current	10	37	48	40	35	33
Total liabilities	34	713	812	1,090	871	1,001
Accumulated deficit	(755)	(1,962)	(2,378)	(2,962)	(3,375)	(3,727)
Total stockholders' equity	117	(242)	(447)	(587)	(489)	(500)
Total liabilities and equity	152	469	362	504	383	502
Common shares outstanding (cover page) millions of shares	109	398	436	674	853	1,028

Fiscal years (IBRX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(92)	(347)	(417)	(583)	(414)	(351)
Stock-based compensation	2	57	40	49	34	37
Depreciation and amortization	9	14	18	19	18	16
Net cash from operating activities	(70)	(274)	(338)	(367)	(391)	(305)
Purchases of property and equipment	3	34	78	31	7	4
Net cash from investing activities	(21)	(85)	27	(30)	(12)	(150)
Proceeds from issuing common stock	86	165	60	—	—	—
Share repurchases	0	0	—	—	—	—
Net cash from financing activities	87	505	234	558	282	400
Net change in cash	(41)	146	(76)	161	(122)	(54)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
ImmunityBio	76	51	(66)*	1.1B	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Anavex Life Sciences	118	not reported	(9.1)*	92.7M	13.0 quarters	Q3 FY26 10-QJun 30, 2026
Immunome	218	0	(62)*	113.6M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Anaptysbio	134	27*	(27)*	29.9M	6.2 quarters	Q4 FY26 10-KTJun 30, 2026
Amphastar Pharmaceuticals	224	184	51*	42.5M	—	Q2 FY26 10-QJun 30, 2026
Pacira BioSciences	206	192	57*	39.9M	—	Q2 FY26 10-QJun 30, 2026
Phibro Animal Health	76	387	26	not reported	—	Q1 FY27 10-QSep 30, 2026
uniQure	98	5.2	(48)*	70.1M	2.6 quarters	Q3 FY26 10-QSep 30, 2026
Cogent Biosciences	181	not reported	(77)*	173.5M	10.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.